The Valley Desk

NCT06890884 · Interventional trial

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Overall registry status Recruiting

Phase 2

Conditions Lymphoma, Large B-Cell, Diffuse

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov